As the Dutch government gets more aggressive about controlling the cost of medicines, the pharmaceutical industry is firing back by arguing the business climate is “under pressure” and questioning policies that are “increasingly undermining” the ability to develop and market new drugs.

The statement from the pharmaceutical committee of the American Chamber of Commerce in the Netherlands follows remarks by Bruno Bruins, the minister for medical care, who wants prices justified, has expressed interest in compulsory licensing, suggested reviewing market exclusivity for orphan drugs, and supports “magisterial preparation,” which allows pharmacists to make competitive treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy